drugset / Trial / NCT06280690
SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia
Non-randomizedSequentialOpen-labelDiagnostic
Summary
This will be the first trial investigating whether tumor targeted fluorescence is able to discriminate invasive T1 carcinoma / High grade dysplasia from Low grade dysplasia/normal tissue during endoscopic intraluminal resection. This will be done using the CEA-targeted fluorescent probe SGM-101.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2025-04-30
- Completion
- 2025-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGM-101 | Monoclonal antibody | 5 mg | — |
| Subject | SGM-101 | Monoclonal antibody | 10 mg | — |